Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — 2020 Edwards Lifesciences Virtual Investor Conference
16 slides from Edwards Lifesciences's conference presentation, Dec 10, 2020
Slide 1: 2020 Investor Conference: Surgical Structural Heart
2020 Investor Conference Surgical Structural Heart
Slide 2: Surgical Structural Heart brings leading innovation
Surgical Structural Heart brings leading innovation • Current $1.8B surgical structural heart market expected to grow mid-single digits through 2026 • We extended our leadership as the partner of choice for cardiac surgeons with three product launches in 2020 • We continue to bring life-saving surgi
Slide 3: Adult cardiac surgery continues to grow mid-single digits driven by awareness and an aging population
Adult cardiac surgery continues to grow mid-single digits driven by awareness and an aging population Surgical Aortic Valve Developed Regions Emerging Regions Replacement Growth in emerging regions equally offset decline in developed regions Surgical Mitral Valve Replacement and Repair Continued glo
Slide 4: Surgical aortic cases continue to grow in segments and emerging regions with less TAVR impact
Surgical aortic cases continue to grow in segments and emerging regions with less TAVR impact Surgical Aortic Procedures (U.S. & EU) Aortic Patients Best Treated Surgically Growth (20-26) Isolated ssAS1 Combined ssAS1 Combined Moderate AS Younger, active patients who Patients with complex disease Pa
Slide 5: Less than 2% of mitral valve disease patients are treated today
Less than 2% of mitral valve disease patients are treated today, with minimal transcatheter cannibalization Surgical Mitral Procedures (U.S. & EU) Mitral Patients Best Treated Surgically Growth (20-26) Functional MR Degenerative MR Rheumatic, Surgical low risk degenerative Patients with complex Pati
Slide 6: We continue to generate robust clinical evidence for our leading RESILIA tissue technology
We continue to generate robust clinical evidence for our leading RESILIA tissue technology Anti-calcification to improve tissue durability RESILIA Tissue Technology Residual aldehydes on RESILIA permanently Capped aldehydes block tissue attract calcium caps residual aldehydes calcium EU Feasibility
Slide 7: INSPIRIS is now the leading aortic surgical valve in the world
INSPIRIS is now the leading aortic surgical valve in the world • Provides RESILIA tissue and VFit technology for potential future valve-in-valve procedures • #1 implanted aortic surgical valve in the U.S. and Japan, launching in China in 2021 • Continuing adoption across U.S. and Europe 12/10/2020 7
Slide 8: KONECT addresses key unmet needs of patients and drives growth in 2021
KONECT addresses key unmet needs of patients and drives growth in 2021 • Launched in the U.S. in June 2020 as the first pre-assembled, ready-to-implant tissue conduit • Designed for complex aortic valve patients with combined aortic root disease • Impacts ~7,500 surgical procedures annually in the U
Slide 9: MITRIS is designed for active mitral patients who might otherwise receive a mechanical valve
MITRIS is designed for active mitral patients who might otherwise receive a mechanical valve • Differentiating RESILIA tissue, ease-of-use enhancements, and valve-in-valve compatibility • Growth opportunity as 60% of global mitral valve replacement patients receive a mechanical valve • Launching in
Slide 10: HARPOON transforms surgery for many patients with degenerative mitral regurgitation
HARPOON transforms surgery for many patients with degenerative mitral regurgitation • Standardizing mitral repair with an echo- guided, beating-heart procedure • Launched in 2020 with potential to convert ~20k surgical repair patients across the U.S., Europe, and Japan • Started the RESTORE U.S. piv
Slide 11: Our strategy will provide a balanced portfolio and will extend patient impact
Our strategy will provide a balanced portfolio and will extend patient impact Surgical Structural Heart Revenue by Segment Aortic Mitral Other Lower contribution from SAVR Current Higher mitral growth contribution Future More surgical solutions for unmet needs 12/10/2020 11
Slide 12: 2021 Global Sales Outlook
2021 Global Sales Outlook Headwinds Tailwinds $900M Continued TAVR Adoption of RESILIA conversion in U.S. & EU $800M products Overall healthcare Accelerated mech-to-tissue budget constraints conversion 2021E Surgical Structural Heart Estimated Global Sales 12/10/2020 12
Slide 13: Executive Summary
Executive Summary • The Surgical Structural Heart market is forecast to grow in areas with unmet patient needs • Our innovation strategy focuses on transforming surgical patients' lives with life-saving surgical technologies 12/10/2020 13
Slide 14: Important Safety Information: INSPIRIS RESILIA Aortic Valve
Important Safety Information: INSPIRIS RESILIA Aortic Valve Indications: For use in replacement of native or prosthetic aortic heart valves. Contraindications: There are no known contraindications with the use of the INSPIRIS RESILIA aortic valve. Complications and Side Effects: Thromboembolism, val
Slide 15: For professional use. Indications, contraindications, warnings
For professional use. For a listing of indications, contraindications, warnings, precautions and adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Artic
Slide 16: Helping Patients is Our Life's Work
P| PP TN Re ND, ave Edwards Helping Patients is Our Life’s Work, and, now) pe?
Edwards Lifesciences — 2020 Edwards Lifesciences Virtual Investor Conference on 6ix